Zimbabwe has turned down a significant US health deal valued at 367 million US dollars (272 million pounds) over five years due to Washington's demand for sensitive data.
This rejection came to light after a official document from December was leaked, revealing that President Emmerson Mnangagwa believed the deal was "unbalanced".
An official spokesman has since explained that the United States was requesting health data for scientific study and commercial purposes but refused to guarantee the benefits from any future vaccines.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued talks to secure a agreement agreeable to both sides so the country's vital HIV treatment initiative can continue.
Broader Background
This rejection follows a similar situation in neighbouring Kenya, where a high court suspended a similar deal with the US following concerns were raised about the security of Kenyans' health data.
After returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had overseen aid for the US government, but Trump argued its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance openness and accountability.
As per statements, 16 African countries have to date agreed to similar health pacts, constituting over $18.3bn in new funding.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment through American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, with no equivalent promise of access to any medical innovations – like new medicines or tests – that could result from that provided information," Mangwana explained.
"In essence, our nation would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our people should a new health crisis emerge."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of one-on-one deals were disrupting systems previously set up via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage future pandemics.
"This framework is intended to guarantee that when a nation provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future collaboration might be arranged in a way that respects the sovereignty and interests of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the government's concerns, but suggested that negotiations need to persist since a large portion of the country's HIV programmes were funded by foreign aid.
"In cases where technical issues arise, including those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group added.
The halted deal underscores the complex challenges between accepting vital foreign assistance and safeguarding local interests in an ever more data-driven world.